Skip to content
Try Mental Wellness – Lifestyle
Author:
ImPact Biotech
ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment
October 23, 2026
ImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updates
September 9, 2026
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
May 30, 2026
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
May 16, 2026